Termination by Allergan. Allergan may terminate this Agreement with respect to one or more countries included in the Territory upon 30 days' prior written notice to ASTI if Allergan elects for any reason to discontinue commercialization of the Licensed Product in such country.
Termination by Allergan. (a) Allergan may terminate this Agreement by giving ninety (90) days prior written notice to ACADIA at any time after completion of the Research Term.
(b) At any time during the Research Term after the second (2nd) anniversary of the Effective Date, Allergan may terminate this Agreement by giving written notice to ACADIA within ninety (90) days after receipt of notice of a Change in Control (as defined in Section 16.14). In the event Allergan terminates this Agreement pursuant to this Section 13.3(b), then notwithstanding any contrary provision of this Agreement, the licenses granted to Allergan pursuant to Sections 7.1(a), 7.1(b) and 7.2 shall continue in full force and effect and shall be exclusive even as to ACADIA (or the surviving entity following such Change in
Termination by Allergan. Allergan may terminate this Agreement (a) [...***...] if Licensee has not launched the Product within [...***...] after receipt of the Pricing Approval of the Product in such country and (b) otherwise in any other country in the Territory, if Licensee has not launched the Product within [...***...] after receipt of the Pricing Approval of the Product in such country, except that notwithstanding the foregoing, if Pricing Approval of the Product has already been received in a country in the Territory as of the Effective Date, Allergan may terminate this Agreement in such country if Licensee has not launched the Product in such country within [...***...] after the Effective Date.
Termination by Allergan. (a) After the First Commercial Sale in the Field in the Territory, ALLERGAN shall have the right to terminate this Agreement at will upon one hundred eighty (180) days’ prior written notice.
(b) After the receipt by MAP of a complete response letter (or its equivalent) for Product from the FDA which, notwithstanding Section 8.8, in ALLERGAN’s sole discretion made in good faith, would require actions by MAP that would be likely to result in either: (i) ALLERGAN incurring Development expenses estimated to be in excess of [***] to obtain Initial Indication Approval; or (ii) a delay in the Initial Indication Approval by more than [***] from receipt of such complete response letter (or its equivalent) for Product from the FDA, ALLERGAN shall have the right to terminate this Agreement at will upon written notice to MAP.
Termination by Allergan. Allergan may terminate this Agreement by giving ninety (90) days prior written notice to ACADIA, but in no event may Allergan terminate this Agreement pursuant to this Section 12.3 prior to the first anniversary of the Effective Date hereof.
Termination by Allergan. Allergan, in its discretion, may terminate this Agreement at any time, on a country by country basis, or in its entirety, upon delivery by Allergan to Ista of ninety (90) days prior notice thereof.
Termination by Allergan. Allergan may terminate this Agreement (a) upon [*] days’ prior written notice to UroGen if such notice is given prior to the First Commercial Sale of a Licensed Product in a country in the Territory or (b) upon [*] days’ prior written notice to UroGen if such notice is given following the First Commercial Sale of a Licensed Product in a country in the Territory, provided that, for clarity and without limiting any other right of Allergan under this Agreement, Allergan shall at all times have the right to suspend or discontinue the use of any Licensed Product for bona fide safety or efficacy concerns immediately upon Allergan’s delivery to UroGen of a notice of termination under this Section 11.2.2.
Termination by Allergan. 8.4.1 If, for any Commercial Year, INSPIRE fails to: (1) make at least eighty-five percent (85%) of the total Presentations required by Section 3.3 for Elestat for such Commercial Year; or (2) subject to ALLERGAN’s performance of its obligations under Sections 3.2.1 and 3.9.2, achieve fifteen percent (15%) of the applicable Elestat annual U.S. Net Sales forecast set forth on Schedule B; ALLERGAN shall have the right to terminate this Agreement, which right must be exercised within sixty (60) days from the end of such Commercial Year. If ALLERGAN terminates this Agreement pursuant to this Section 8.4.1, INSPIRE shall not be entitled to Elestat Tail Payments pursuant to Section 4.2.1.
8.4.2 In the event that INSPIRE, through merger, acquisition, or otherwise, becomes an Affiliate of a Direct Competitor, ALLERGAN shall be entitled to terminate this Agreement, which right must be exercised within three (3) months from the occurrence of such event. In the event that INSPIRE becomes an Affiliate of a Direct Competitor within thirty (30) months of the Effective Date and ALLERGAN exercises its right to terminate this Agreement pursuant to this Section 8.4.2, INSPIRE shall not be entitled to any Elestat Tail Payments pursuant to Section 4.2. If INSPIRE becomes an Affiliate of a Direct Competitor more than thirty (30) months after the Effective Date, and ALLERGAN exercises its right to terminate this Agreement pursuant to this section 8.4.2, then INSPIRE shall be entitled to Elestat Tail Payments under Section 4.2.
Termination by Allergan. Notwithstanding the foregoing, ALLERGAN shall have the right to terminate this Agreement without cause and without penalty any time after the completion of the twelve (12) quarters of R&D under Article 2.2 by providing sixty (60) days prior written notice to SHSC of its intent to terminate.
Termination by Allergan. Allergan shall have the right to terminate this Agreement at will upon *** days prior written notice to Serenity.
